RecruitingNCT05785052

Biomarkers of Renal Cancer

Sponsor

Biorek S.R.L.

Enrollment

1,000 participants

Start Date

Jun 11, 2019

Study Type

OBSERVATIONAL

Conditions

Renal Cell Carcinoma Tumor, Solid Oncocytoma Angiomyolipoma

Summary

The aim of the present study is the identification, in liquid biopsies, of a new molecular panel able to discriminate renal cancer patients from controls, to discriminate patients with a malignant lesion from those with a benign mass, to determine aggressiveness of RCC, and to differentiate the most common histological subtypes of RCC (clear cell, papillary 1, papillary 2, and chromophobe). This new molecular panel will be combined with clinical parameters to provide a screening test and to improve the accuracy and specificity of diagnosis, prognosis, and histological classification of renal cancer.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is collecting blood and tissue samples to identify biological markers (biomarkers) that could help diagnose kidney cancer more accurately and at an earlier stage. Researchers will compare samples from patients with a suspected kidney mass to those from healthy kidney donors or people undergoing routine urological procedures. **You may be eligible if (kidney mass patients):** - You are a man or woman over 18 years old - This is your first diagnosis of a kidney mass - You are of Caucasian ethnicity - You have signed an informed consent form **You may be eligible if (healthy controls):** - You are a living kidney donor or are undergoing a urological procedure for a non-cancer reason **You may NOT be eligible if:** - You have had another cancer in the past 5 years - You have a genetic cancer syndrome - You have had a previous kidney tumor - You have urothelial (bladder or ureter) cancer - You have end-stage kidney disease requiring dialysis - You have cancer in both kidneys Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.